|Bid||0.000 x 3000|
|Ask||0.000 x 800|
|Day's Range||47.040 - 47.488|
|52 Week Range||46.290 - 58.900|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.96|
|Expense Ratio (net)||0.11%|
Among the emerging market (VEU) currencies, the Argentinian peso, Turkish (TUR) lira, Indonesia rupiah, and Indian rupee are declining to all-time lows. The US dollar is also strengthening against all major currencies, including those of emerging markets. As the US dollar strengthens and interest rates rise, the cost of servicing US debt for other countries goes up.
A few countries have been spared in the global massacre and will likely maintain their strength. As such, we have highlighted those country ETFs that delivered near to double-digit returns in the first half.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes various products for oral health, wellness, nutrition, and skin health. The Consumer Healthcare segment reported a 3% fall in its YoY (year-over-year) revenue to ~2.0 billion pounds in Q1 2018 compared to Q1 2017.
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term. The tension in the Korean Peninsula could be the biggest danger to market stability in the long run. As long as the balance is maintained between US interests and North Korea’s ambitions, the status quo is likely to prevail.
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.
What Triggered the Stock Market Panic This Month? The last two trading sessions on February 2 and 5 have left many investors worried about assets in the bond (BND) and stock markets. The sell-off in the stock market began after the US employment report was published on Friday, February 2.
As we saw earlier, Wall Street analysts are estimating that AstraZeneca (AZN) will report EPS (earnings per share) of $0.47 on revenues of $5.4 billion in 4Q17, a 2.5% decline compared to $5.6 billion in 4Q16. AstraZeneca stock has risen 32% over the last 12 months. Analysts’ estimates show that the stock has a potential to return 8.6% over the next 12 months.
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 298 million pounds from the sale of its meningitis vaccines, which is year-over-year (or YoY) growth of 31% on a reported basis and 25% on a constant exchange rate (or CER) basis. The company’s meningitis vaccines portfolio witnessed sales worth 143 million pounds in the US market in 3Q17, which is YoY growth of 44% on a reported basis and 36% on a CER basis. GlaxoSmithKline earned revenues close to 103 million pounds from the sale of meningitis vaccines in Europe in 3Q17, which is a YoY rise of 34% on a reported basis and 30% on a CER basis.
To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators, Anoro and Incruse. The company also expects to see COPD patients who are at higher risk of exacerbations to shift from open triple therapy to closed triple therapy such as the recently launched Trelegy Ellipta.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.